Key result
Atrial fibrillation in end-stage renal disease was associated with increased mortality (26.9 vs 13.4 per 100 patient-years) and stroke (5.2 vs 1.9 per 100 patient-years) compared to no AF.
Why the study?
What is the incidence, prevalence, and impact of atrial fibrillation in ESRD patients, and does warfarin provide a protective effect against stroke?
Population
Patients with end-stage renal disease on dialysis. Meta-analysis of 25 studies.
Comparison
Warfarin anticoagulation vs No warfarin or ESRD patients without atrial…
Design
Meta-analysis
Authors
Loading...
AF in ESRD raises mortality and stroke risk; leaves open anticoagulation benefit, warranting RCTs.
Meta-Analysis
What is the incidence, prevalence, and impact of atrial fibrillation in ESRD patients, and does warfarin provide a protective effect against stroke?
Absolute Event Rate: 26.9% vs 13.4%
Atrial fibrillation is highly prevalent in ESRD patients and associated with increased mortality and stroke, while current data do not support a protective effect of warfarin, highlighting the need for randomized trials.
Zimmerman et al. (2012) conducted a meta-analysis in End-stage renal disease and atrial fibrillation. Atrial fibrillation vs. ESRD patients without AF was evaluated on Mortality. Atrial fibrillation in end-stage renal disease was associated with increased mortality (26.9 vs 13.4 per 100 patient-years) and stroke (5.2 vs 1.9 per 100 patient-years) compared to no AF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: